In November 2023, we announced an updated collaboration with our established partner, Bayer, for a select set of precision oncology programs. The collaboration will leverage our state-of-the-art capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need. Under the terms of the agreement, we may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales.
In December 2021, we entered into a multi-year, strategic collaboration with Roche and Genentech in key areas of neuroscience and an oncology indication. Through the partnership, we are working with both Roche and Genentech's R&D units to leverage our Recursion OS and Maps of Biology, along with extensive single-cell perturbation screening data from Roche and Genentech, to rapidly identify novel biological relationships to initiate and advance therapeutic programs. Together we may initiate up to 40 programs over a decade or longer.
In July 2023, we entered into a strategic collaboration with NVIDIA to accelerate the development of our groundbreaking AI foundation models for biology and chemistry on NVIDIA DGX™ Cloud. We intend to optimize and distribute these models for possible commercial license or release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. In November 2023, we committed to working with NVIDIA to expand BioHive-1, our on-premise supercomputer, to increase the computational capacity by over 4x. We project that upon completion and benchmarking, BioHive-1 will be in the top 50 most powerful supercomputers in the world across any industry (according to the Top500 list) and will be the most powerful supercomputer owned and operated by any biopharma company.
In November 2023, we entered into a collaboration with Tempus to gain preferred access to one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, we believe we have an opportunity to improve the speed, precision and scale of therapeutic development in oncology.
In December 2023, we entered into a collaboration with Enamine to generate and design enriched compound libraries for the global drug discovery industry. By leveraging Recursion’s MatchMaker tool to identify compounds in the Enamine REAL Space predicted to bind to high-value targets, the companies believe they can generate more powerful compound libraries for drug discovery purposes. Enamine may offer the resulting libraries to customers for purchase and will co-brand any libraries under both the Enamine and MatchMaker trademarks.
In order to achieve our mission, we partner with leading biotechnology companies, pharmaceutical companies and academic research institutions to identify novel therapeutics and unlock biological insights using our discovery technology. Our partnering efforts take two primary forms: discovery platform partnerships and asset development partnerships.
In addition to NCEs, the Recursion Map may discover new uses for known chemical entities owned or controlled by third parties. In such circumstances, we may in-license rights to these assets to advance these programs internally.
We have collaborated with third parties to broadly explore diverse disease domains (e.g., fibrosis, neuroscience, and oncology). Collaborations leverage our partner's deep domain expertise and Recursion's unique capability to map and navigate complex biology to identify and rapidly advance potential therapeutics.
Connect with us at firstname.lastname@example.org.